Bicara Therapeutics (BCAX) Interest Expenses (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Interest Expenses of $108.8 million for Q1 2026, up 108657.0% year-over-year from N/an in Q1 2025, and up 108657.0% quarter-over-quarter from $100000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Interest Expenses (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at $108.8 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 108657.0% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $108.8 million (up 36152.33% YoY), while the FY2025 annual figure was $97.8 million, up 65.68% from the prior year.
- Interest Expenses for Q1 2026 stood at $108.8 million, up from $100000.0 in the prior quarter.
- The five-year high for Interest Expenses was $108.8 million in Q1 2026, with the low at $100000.0 in Q3 2024.
- The 4-year median for Interest Expenses is $100000.0 (2024), against an average of $20.9 million.
- The sharpest annual moves came in 2024 and 2026: Interest Expenses tumbled 99.73% in 2024, then soared 108657.0% in 2026.
- Bicara Therapeutics' Interest Expenses stood at $37.7 million in 2023, then sank by 99.73% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then jumped by 108657.0% to $108.8 million in 2026.
- Business Quant data shows BCAX's Interest Expenses at $108.8 million in Q1 2026, $100000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 213.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 213.54 Mn |
| Jun 30, 2026 | 213.54 Mn |
| Mar 31, 2026 | 108.76 Mn |
| Mar 31, 2026 | 108.76 Mn |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 20.50 Mn |
| Jun 30, 2025 | 20.50 Mn |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Dec 31, 2023 | 37.71 Mn |
| Dec 31, 2023 | 37.71 Mn |